GSK vs. LLY: GSK vs. Eli Lilly Stock Comparison
How do GSK (GSK) and Eli Lilly (LLY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
GSK (GSK) and Eli Lilly (LLY) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.
Eli Lilly (LLY) trades as ordinary local shares, while GSK (GSK) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | GSK | LLY |
|---|---|---|
| Name | GSK plc ADR | Eli Lilly and Company |
| Country/Region | United Kingdom | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Pharmaceuticals | Pharmaceuticals |
| GICS Sub-Industry | Pharmaceuticals | Pharmaceuticals |
| Market Capitalization | 100.88 billion USD | 1,206.07 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | NYSE |
| Listing Date | March 28, 1980 | June 1, 1972 |
| Security Type | ADR | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | GSK | LLY |
|---|---|---|
| Total Return (1Y) | 13.73% | 52.36% |
| Total Return (3Y, Annualized) | 18.65% | 34.18% |
| Total Return (5Y, Annualized) | 7.97% | 41.08% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | GSK | LLY |
|---|---|---|
| Volatility (1Y, Annualized) | 26.25% | 35.34% |
| Beta (5Y) | 0.31 | 0.40 |
| Max Drawdown (5Y) | -37.63% | -34.48% |
| Avg. Volume (3M) | 4.05M | 2.52M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | GSK | LLY |
|---|---|---|
| Sharpe Ratio (1Y) | 0.36 | 1.36 |
| Sortino Ratio (1Y) | 0.56 | 2.29 |
Profitability
ROE (TTM)
Both GSK (GSK) at 28.27% and Eli Lilly (LLY) at 86.02% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
28.27%
- Max
- 109.18%
- GSK
- 28.27%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
86.02%
- Max
- 109.18%
- LLY
- 86.02%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Eli Lilly (LLY) at 31.90% keeps the most of each sales dollar — above its industry’s net margin range — and GSK (GSK) at 12.97% also retains a top-quartile share.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
12.97%
- Max
- 18.05%
- GSK
- 12.97%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
31.90%
- LLY
- 31.90%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both GSK (GSK) at 32.14% and Eli Lilly (LLY) at 53.66% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
32.14%
- Max
- 83.12%
- GSK
- 32.14%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
53.66%
- Max
- 83.12%
- LLY
- 53.66%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | GSK | LLY |
|---|---|---|
| ROE (TTM) | 28.27% | 86.02% |
| ROA (TTM) | 9.24% | 21.06% |
| Net Margin (TTM) | 12.97% | 31.90% |
| Operating Margin (TTM) | 32.14% | 53.66% |
| Gross Margin (TTM) | 73.79% | 83.63% |
Growth
Revenue Growth
Both GSK (GSK) at 4.11% and Eli Lilly (LLY) at 44.70% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Both GSK (GSK) at 123.15% and Eli Lilly (LLY) at 95.99% sit in the top peer quartile for EPS growth, so each is compounding per-share earnings faster than typical industry peers.
Growth Metrics
| Metric | GSK | LLY |
|---|---|---|
| Revenue Growth (YoY) | 4.11% | 44.70% |
| Revenue Growth (3Y CAGR) | 3.66% | 31.69% |
| EPS Growth (YoY) | 123.15% | 95.99% |
| EPS Growth (3Y CAGR) | -27.63% | 51.71% |
Financial Strength
Current Ratio (MRQ)
Both GSK (GSK) at 0.86 and Eli Lilly (LLY) at 1.39 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.86
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- GSK
- 0.86
- Min
- 0.10
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.39
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- LLY
- 1.39
- Min
- 0.10
Debt / Equity (MRQ)
Both GSK (GSK) at 1.30 and Eli Lilly (LLY) at 1.23 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.30
- Max
- 1.42
- GSK
- 1.30
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.23
- Max
- 1.42
- LLY
- 1.23
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | GSK | LLY |
|---|---|---|
| Current Ratio (MRQ) | 0.86 | 1.39 |
| Debt / Equity (MRQ) | 1.30 | 1.23 |
| Net Debt / EBITDA | 1.88 | 0.96 |
Dividends
Dividend Yield (TTM)
Both GSK (GSK) at 1.57% and Eli Lilly (LLY) at 0.49% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.57%
- GSK
- 1.57%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.49%
- LLY
- 0.49%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Both GSK (GSK) at 63.33% and Eli Lilly (LLY) at 21.71% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
63.33%
- GSK
- 63.33%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
21.71%
- LLY
- 21.71%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | GSK | LLY |
|---|---|---|
| Dividend Yield (TTM) | 1.57% | 0.49% |
| Dividend Payout Ratio (TTM) | 63.33% | 21.71% |
Valuation
P/E Ratio (TTM)
GSK (GSK) at 17.54 is near its industry’s usual P/E ratio, while Eli Lilly (LLY) at 43.95 sits in the richer quartile — LLY needs stronger growth or earnings quality to justify the premium.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
17.54
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- GSK
- 17.54
- Q1
- 13.30
- Min
- 0.07
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
43.95
- Max
- 85.34
- LLY
- 43.95
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
GSK (GSK) at 3.01 sits in the cheaper P/S ratio quartile while Eli Lilly (LLY) at 13.95 prices around its industry’s middle — GSK costs less per dollar of sales, though read it alongside growth and margins.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.01
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- GSK
- 3.01
- Min
- 0.01
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.95
- Max
- 58.18
- Q3
- 25.77
- LLY
- 13.95
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
GSK (GSK) at 4.02 sits near its industry’s typical P/B ratio, while Eli Lilly (LLY) at 29.96 prices above its benchmark range — LLY looks rich relative to book.
GSK
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.02
- Max
- 13.53
- Q3
- 6.54
- GSK
- 4.02
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
29.96
- LLY
- 29.96
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | GSK | LLY |
|---|---|---|
| P/E Ratio (TTM) | 17.54 | 43.95 |
| P/S Ratio (TTM) | 3.01 | 13.95 |
| P/B Ratio (MRQ) | 4.02 | 29.96 |
| Free Cash Flow Yield (TTM) | 5.28% | 0.77% |